By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with an exclusive option to license a diagnostic platform for central nervous system cancer patients undergoing radiotherapy, the company said. CNSide is a proprietary assay that...

By Daniella Parra Eterna Therapeutics Inc. (Nasdaq: ERNA) is partnering with Lineage Cell Therapeutics, Inc. to develop stem cell lines for central nervous system diseases, the company said. Eterna’s mRNA gene-editing approach and Lineage’s expertise in gene editing aim to...

  By Karen E. Roman Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq: BIIB) evaluating 150 patients using the Octave Precision Care Solution....

By Karen E. Roman Plus Therapeutics, Inc. (Nasdaq: PSTV) announced treatment of the first patient in Part B of a trial for the treatment of leptomeningeal metastases from solid tumors. Leptomeningeal metastases are complication of cancer in which the primary cancer spreads to...

By Healthcare Edge Editorial Staff Eterna Therapeutics Inc. (Nasdaq: ERNA), a life science company focused on the potential of mRNA cell engineering, said it appointed Dorothy Clarke to its board of directors. Dorothy’s extensive experience will continue to help deliver...

By Healthcare Edge Editorial Staff ProSomnus, Inc. (NASDAQ: OSA), a provider of an alternative treatment for Obstructive Sleep Apnea, released new clinical trial data showing that the First Line Obstructive Sleep Apnea Treatment study (FLOSAT) is on track to achieve all...

By Daniella Parra Comera Life Sciences Holdings (Nasdaq: CMRA) said it published data showing caffeine’s potential to reduce viscosity in subcutaneous formulations of monoclonal antibodies. The studies demonstrated caffeine’s positive influence on pharmacokinetics and its compatibility with monoclonal antibody ipilimumab,...

By Daniella Parra Avertix Medical said it was collaborating with the Heart & Rhythm Institute of Trinity to bring an FDA-approved implantable heart attack detection and warning system to patients with high-risk coronary disease, it said. The implant, called the...

By Daniella Parra Sparrow Pharmaceuticals said it was extending the trial phase for SPI-62, a potential treatment for ACTH-dependent Cushing’s syndrome. The goal is to gather new long-term safety and tolerability data, with continued monitoring of SPI-62’s effects on signs...

  Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, presented promising outcomes from the ReSPECT-LM clinical study at the SNO/ASCO CNS Cancer Conference. The study assesses rhenium (186Re) obisbemeda’s effectiveness in treating leptomeningeal metastases (LM), it said. Rhenium (186Re)...